Pregnancy Clinical Trial
Official title:
Impact of Conditional Financial Support on Pregnancy Outcomes in Pregnant Women With Low Incomes: Pragmatic Randomized Cluster Trial, With Parallel Arms
Verified date | November 2020 |
Source | Centre Hospitalier Universitaire Dijon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to evaluate the impact of financial support on improving the management of prenatal care in pregnant women with low incomes. The judgment criterion is clinically pertinent: complications of pregnancy. This study also aims to evaluate attitudes to this approach through a qualitative survey. It is planned to include 4000 women distributed into two arms of 2000 each. One group will receive financial support (prepaid payment card credited for each consultation attended according to the scheduled follow-up as recommended by the Haute Autorité de Santé); the other group will not. The management of the pregnancy for both groups will not be modified.
Status | Completed |
Enrollment | 3787 |
Est. completion date | September 9, 2020 |
Est. primary completion date | September 9, 2020 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pregnant women - Age > 18 years - 1st consultation before the 26th week of amenorrhea - Recipient of free health care (Couverture Maladie Universelle, Couverture Maladie Universelle-Complémentaire) - Who have provided written informed consent to take part in the study Exclusion Criteria: - Persons without national health insurance cover - Persons unable to understand the information on the study, despite the help of a translator or a person of trust if necessary - Persons under guardianship |
Country | Name | City | State |
---|---|---|---|
France | CHRU de BESANCON | Besancon | |
France | CHRU de BREST | Brest | |
France | CHU de DIJON | Dijon | |
France | APHP maternité Kremlin Bicêtre | Kremlin-bicetre | |
France | CHRU de LILLE | Lille | |
France | APHM Hôpital Nord | Marseille | |
France | APHP Hopital Robert Debré | Paris | |
France | Chu Saint Etienne | Saint Etienne | |
France | Chu Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Dijon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Maternal morbidity, mortality and rate of caesarean sections | A composite outcome measure consisting of multiple measures: maternal mobidity, mortality and rate og caesarean sections | Participants will be followed for the duration of hospital stay and for a maximum of one month after the term date. | |
Other | Number of scheduled consultations attended in agreement with the minimal follow-up recommendations of the Haute Autorité de Santé | Participants will be followed for the duration of hospital stay and for a maximum of one month after the term date. | ||
Other | Interview with a sociologist to evaluate perception of the intervention and evaluation of its perceived impact in follow-up of the pregnancy | About 6 weeks after delivery | ||
Other | Differential cost-effectiveness ratio associated with the financial support compared with the absence of support and expressed in terms of cost per complication avoided | Participants will be followed for the duration of hospital stay and for a maximum of one month after the term date. | ||
Primary | Occurence of complication(s) of pregnancy, wether maternal, fetal or neonatal | Participants will be followed for the duration of hospital stay and for a maximum of one month after the term date. | ||
Secondary | Neonatal morbidity, mortality and rate of transfer of the newborn to a neonatal care unit. | A composite outcome measure consisting of multiple measures: neonatal morbidity, mortality and rate of tranfer of the newborn to a neonatal care unit | Participants will be followed for the duration of hospital stay and for a maximum of one month after the term date. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |